PENTIXAPHARM HOLDING N AG Net Assets
PENTIXAPHARM HOLDING N AG net assets. Based on the latest financial reports, PENTIXAPHARM HOLDING N AG (PTP) has net assets worth €28.47 Million EUR (≈ $33.29 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€38.51 Million ≈ $45.02 Million USD) and total liabilities (€10.04 Million ≈ $11.74 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore PENTIXAPHARM HOLDING N AG net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €28.47 Million |
| % of Total Assets | 73.93% |
| Annual Growth Rate | 5.9% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 25.62 |
Net Assets of PENTIXAPHARM HOLDING N AG (2021–2025)
Net assets of PENTIXAPHARM HOLDING N AG from 2021 to 2025. This chart illustrates how PENTIXAPHARM HOLDING N AG's net assets have evolved over time, based on quarterly financial data. See how leveraged is PENTIXAPHARM HOLDING N AG's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for PENTIXAPHARM HOLDING N AG (2021–2025)
The table below shows the annual net assets of PENTIXAPHARM HOLDING N AG from 2021 to 2025. For live market cap and overall valuation, see PENTIXAPHARM HOLDING N AG (PTP) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €35.07 Million ≈ $41.00 Million |
-29.03% |
| 2024-12-31 | €49.41 Million ≈ $57.77 Million |
+1.93% |
| 2023-12-31 | €48.48 Million ≈ $56.68 Million |
+26.04% |
| 2022-12-31 | €38.47 Million ≈ $44.97 Million |
+37.96% |
| 2021-12-31 | €27.88 Million ≈ $32.60 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PENTIXAPHARM HOLDING N AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2398500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
PENTIXAPHARM HOLDING N AG Net Assets Breakdown (December 2025)
PENTIXAPHARM HOLDING N AG net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €63.51 Million | 181.08% |
| Total Equity | €35.07 Million | 100.00% |
PENTIXAPHARM HOLDING N AG Competitors by Market Cap
The table below lists competitors of PENTIXAPHARM HOLDING N AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pacific Bay Minerals Ltd
V:PBM
|
$923.30K |
|
2CUREX AB SEK-10
F:2QE
|
$923.79K |
|
Braemar Plc
LSE:BMS
|
$925.62K |
|
Lyc Healthcare Bhd
KLSE:0075
|
$928.88K |
|
Alveen
PA:MLALV
|
$920.96K |
|
Cake Box Holdings PLC
LSE:CBOX
|
$920.81K |
|
Tlou Energy Ltd
AU:TOU
|
$918.83K |
|
Ribbon Acquisition Corp Rights
NASDAQ:RIBBR
|
$918.72K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PENTIXAPHARM HOLDING N AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 49,415,000 to 35,072,000, a change of -14,343,000 (-29.0%).
- Net loss of 16,511,000 reduced equity.
- Other factors increased equity by 2,168,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-16.51 Million | -47.08% |
| Other Changes | €2.17 Million | +6.18% |
| Total Change | €- | -29.03% |
Book Value vs Market Value Analysis
This analysis compares PENTIXAPHARM HOLDING N AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.23x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.55x to 1.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €1.12 | €1.74 | x |
| 2022-12-31 | €1.49 | €1.74 | x |
| 2023-12-31 | €1.87 | €1.74 | x |
| 2024-12-31 | €1.99 | €1.74 | x |
| 2025-12-31 | €1.42 | €1.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PENTIXAPHARM HOLDING N AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -47.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17753.76%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.19x
- Recent ROE (-47.08%) is below the historical average (-20.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -8.94% | -4223.73% | 0.00x | 1.05x | €-5.28 Million |
| 2022 | -5.10% | -6325.81% | 0.00x | 1.40x | €-5.81 Million |
| 2023 | -15.76% | -31829.17% | 0.00x | 1.51x | €-12.49 Million |
| 2024 | -25.99% | -10883.90% | 0.00x | 1.36x | €-17.78 Million |
| 2025 | -47.08% | -17753.76% | 0.00x | 1.19x | €-20.02 Million |
Industry Comparison
This section compares PENTIXAPHARM HOLDING N AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PENTIXAPHARM HOLDING N AG (PTP) | €28.47 Million | -8.94% | 0.35x | $922.50K |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About PENTIXAPHARM HOLDING N AG
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunologic… Read more